Blueprint Medicines Corp (BPMC)
129.46
0.00 (0.00%)
USD |
NASDAQ |
Aug 13, 16:00
Blueprint Medicines Max Drawdown (5Y)
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| July 31, 2025 | 69.50% |
| June 30, 2025 | 69.50% |
| May 31, 2025 | 69.50% |
| April 30, 2025 | 69.50% |
| March 31, 2025 | 69.50% |
| February 28, 2025 | 69.50% |
| January 31, 2025 | 69.50% |
| December 31, 2024 | 69.50% |
| November 30, 2024 | 69.50% |
| October 31, 2024 | 69.50% |
| September 30, 2024 | 69.50% |
| August 31, 2024 | 69.50% |
| July 31, 2024 | 69.50% |
| June 30, 2024 | 69.50% |
| May 31, 2024 | 69.50% |
| April 30, 2024 | 69.50% |
| March 31, 2024 | 69.50% |
| February 29, 2024 | 69.50% |
| January 31, 2024 | 69.50% |
| December 31, 2023 | 69.50% |
| November 30, 2023 | 69.50% |
| October 31, 2023 | 69.50% |
| September 30, 2023 | 69.50% |
| August 31, 2023 | 69.50% |
| July 31, 2023 | 69.50% |
| Date | Value |
|---|---|
| June 30, 2023 | 69.50% |
| May 31, 2023 | 69.50% |
| April 30, 2023 | 69.50% |
| March 31, 2023 | 69.50% |
| February 28, 2023 | 69.50% |
| January 31, 2023 | 67.01% |
| December 31, 2022 | 67.01% |
| November 30, 2022 | 67.01% |
| October 31, 2022 | 63.66% |
| September 30, 2022 | 63.66% |
| August 31, 2022 | 63.66% |
| July 31, 2022 | 63.66% |
| June 30, 2022 | 63.66% |
| May 31, 2022 | 58.35% |
| April 30, 2022 | 56.54% |
| March 31, 2022 | 56.54% |
| February 28, 2022 | 55.74% |
| January 31, 2022 | 55.74% |
| December 31, 2021 | 55.74% |
| November 30, 2021 | 55.74% |
| October 31, 2021 | 55.74% |
| September 30, 2021 | 55.74% |
| August 31, 2021 | 55.74% |
| July 31, 2021 | 55.74% |
| June 30, 2021 | 55.74% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Agenus, Inc. | 98.84% |
| Amgen, Inc. | 24.86% |
| Altimmune, Inc. | 93.57% |
| Amarantus Bioscience Holdings, Inc. | 100.00% |
| Aligos Therapeutics, Inc. | 99.54% |